Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. x. x. a č. 46/2008 Xx. x. x. x nahrazuje xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 11. xxxxxxxxx 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.¹⁾

X xxxxx zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x přijetí xxxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Přílohy X vstoupilo v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2014 x xxxxx xxxx xxxxxxxxx x xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx současně.

¹⁾ Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx xxxxxx xxxxxxx dne 19. xxxxx 2005 v Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX ROK 2014

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. ledna 2014

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Specifické xxxxx" xxxxx látek xx skupin X1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.

LÁTKY X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmaceutická xxxxx, která xxxx xxxxxxxx x následujících xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva v xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu nebo xx ukončené registraci, xxxxxxxxxx xxxxx, látky xxxxxxxxx pouze pro xxxxxxxxxxx xxxxxxx), je xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-androst-1-en-3b,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); bolasteron; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-nor-pregna-4-en-17α-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; klostebol; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4,:2,3]-5α-androstane); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

(b) Xxxxxxxxx** XXX, pokud jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx metabolity x xxxxxxx, ale ne x xxxxxxxx pouze xx ně:

5α-androstan-3α,17α-diol	5-androstendion (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "exogenní" xx vztahuje x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " se xxxxxxxx x látce, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx jsou xxxxxxxx:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (EPO), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);

2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxxxx uvolňující xxxxxxx x xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (GH) x xxxx xxxxxxxxxx faktory x xxxxxxxx xxxxxxx xxxxxxx faktor-1 (IGF-1).

Kromě xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový faktor (XXX), mechanické růstové xxxxxxx (MGF), růstový xxxxxx xxxxxxxx z xxxxxxxx destiček (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), stejně xxxx jakékoliv xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x vaziva, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx;

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx zakázáni xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx za 24 hodin), inhlalačního xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin) x xxxxxxxxxxx, xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx vyšší xxx 1000 ng/ml a xxxxxxxxxx formoterolu x xxxx x koncentraci xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx bude xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky nižší xxx xxxx xxxxxxx xxxxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), zahrnující:

Raloxifen, tamoxifen, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, klomifen, xxx xx x xxxxxxxx xxxxx na ně.

4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Xxxxxxxx;

x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX v xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx protein xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. AICAR)

S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX LÁTKY

Maskovací xxxxx xxxx zakázané. Zahrnují:

Diuretika, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx zakázáno.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. xxxxxxxxx) a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) ve xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Terapeutické výjimky xx tuto xxxxx xxxxx k té, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X KRVÍ A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx krvinek x jim podobných xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), perfluorochemikálie x xxxxxxxxxxx (XXX13), ale xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX A FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxxx infuzí legitimně xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Transfer xxxxxxxx nukleových kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx buněk.

LÁTKY X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až X5 x M1 až X3 xxxxxxxxx xxxx xxxx Při Xxxxxxx xxxxxxxx i následující xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných optických xxxxxxx (xxxx. x- x x-) jsou xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, amfepramon, amfetamin, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, benzfetamin, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, etylefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, hydroxyamfetamin (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx analoga (xxxx. mefedron, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx***, metylendioxymetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx (xxxxxxxxxxxxx), pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

* Následující xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) nejsou xxxxxxxxxx xx Zakázané xxxxx.

** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Efedrin x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxx xxxxxx adrenalinu (epinefrinu) (xxxx. xxxxx, oční xxxxxxxx) xxxx xxxx xxxxxx společně x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.

***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, oxykodon, xxxxxxxxx, xxxxxxxxxx, petidin.

S8. XXXXXXXXXXX

Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxxxxxxxxx (např. "Xxxxx", XXX018, XXX073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

XXXXX XXXXXXXX V XXXXXXXX XXXXXXXX

X1. ALKOHOL

Alkohol (etanol) xx xxxxxxxx pouze Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx zkouškou a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0.10 x/x.

• Automobilový xxxxx (XXX)

• Xxxxxx (WKF)

• Xxxxxxx sporty a xxxxxxxxxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Lukostřelba (XX) (zakázané xxxx Xxxx soutěž)

• Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

• Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

Xxxxxxxxx

Xxxxxx předpis x. 47/2014 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Xx. x. x. byl xxxxxx xxxxxxx předpisem č. 19/2017 Sb. m. s. x účinností xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem jiných xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.